Evidence for the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS)

Area of Science:

• Neuroscience
• Genetics
• Psychiatry

Background:

• Over 11,495 addiction psychiatry articles published since 1990.
• The Genetic Addiction Risk Severity (GARS) test has shown clinical relevance in identifying reward deficiency behaviors.
• Early research linked the DRD2 gene polymorphism to alcoholism, but findings were mixed.

Purpose of the Study:

• To investigate the association between the DRD2 gene and addiction, particularly Alcohol Use Disorder (AUD).
• To clarify the role of DRD2 gene polymorphisms in Reward Deficiency Syndrome (RDS).

Main Methods:

• Meta-analysis of 62 studies on DRD2 rs 1800497 and AUD.
• Examination of DRD2 gene haplotype blocks and AUD/heroin dependence.
• Genome-Wide Association Studies (GWAS) on depression, suicide, and substance use disorders (SUD).

Main Results:

• A meta-analysis confirmed a significant association between DRD2 rs 1800497 and AUD.
• The DRD2 A1 allele haplotype was linked to AUD and heroin dependence.
• GWAS studies confirmed the association of the DRD2 Taq A1 allele with severe alcoholism and suicide behaviors (P=1.77 × 10⁻⁷).
• DRD2 was the top gene signal (P=7.9 × 10⁻¹²) for SUD with multiple substances.

Conclusions:

• The DRD2 gene and its polymorphisms are significant determinants of Reward Deficiency Syndrome (RDS).
• GWAS findings should resolve controversy regarding DRD2's role in addiction.
• The GARS test is a valuable tool for assessing addiction risk related to genetic predispositions.